Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-04

AUTHORS

C. Rothermundt, J. von Rappard, T. Eisen, B. Escudier, V. Grünwald, J. Larkin, D. McDermott, J. Oldenburg, C. Porta, B. Rini, M. Schmidinger, C. N. Sternberg, P. M. Putora

ABSTRACT

BACKGROUND: Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line treatment after first-line therapy with a tyrosine kinase inhibitor (TKI). Recently two phase III trials have demonstrated a potential role for nivolumab (NIV) and cabozantinib (CAB) in this setting. We aimed to estimate the impact of these trials on clinical decision making. MATERIALS AND METHODS: Eleven international experts were asked to provide their treatment strategies for second-line systemic therapy for mccRCC in the current setting and once NIV and CAB will be approved and available. The treatment strategies were analyzed with the objective consensus approach. RESULTS: The analysis of the decision trees revealed everolimus (EVE), axitinib (AXI), NIV and TKI switch (sTKI) as therapeutic options after first-line TKI therapy in the current situation and mostly NIV and CAB in the future setting. The most commonly used criteria for treatment decisions were duration of response, TKI tolerance and zugzwang a composite of several related criteria. CONCLUSION: In contrast to the first-line setting, recommendations for second-line systemic treatment of mccRCC among experts were not as heterogeneous. The agents mostly used after disease progression on a first-line TKI included: EVE, AXI, NIV and sTKI. In the future setting of NIV and CAB availability, NIV was the most commonly chosen drug, whereas several experts identified situations where CAB would be preferred. More... »

PAGES

641-648

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-016-1903-6

DOI

http://dx.doi.org/10.1007/s00345-016-1903-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013796886

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27488984


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Algorithms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Axitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Consensus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decision Support Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decision Trees", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nivolumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kantonsspital St. Gallen", 
          "id": "https://www.grid.ac/institutes/grid.413349.8", 
          "name": [
            "Department of Haematology and Oncology, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rothermundt", 
        "givenName": "C.", 
        "id": "sg:person.01175307510.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175307510.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Children\u2019s Hospital Bern", 
          "id": "https://www.grid.ac/institutes/grid.412353.2", 
          "name": [
            "Department of Nephrology, University Hospital Bern, Bern, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Rappard", 
        "givenName": "J.", 
        "id": "sg:person.01237535151.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237535151.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cambridge", 
          "id": "https://www.grid.ac/institutes/grid.5335.0", 
          "name": [
            "Department of Oncology, Cambridge University Hospitals NHS Foundation Cambridge, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eisen", 
        "givenName": "T.", 
        "id": "sg:person.011012720634.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011012720634.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "B.", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hannover Medical School", 
          "id": "https://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, H\u00e4mostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gr\u00fcnwald", 
        "givenName": "V.", 
        "id": "sg:person.01315730111.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315730111.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "The Royal Marsden Hospital, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larkin", 
        "givenName": "J.", 
        "id": "sg:person.010726400772.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010726400772.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beth Israel Deaconess Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239395.7", 
          "name": [
            "Beth Israel Deaconess Medical Center, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McDermott", 
        "givenName": "D.", 
        "id": "sg:person.0656541200.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oslo University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.55325.34", 
          "name": [
            "Department of Medical Oncology, Norwegian Radium Hospital, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oldenburg", 
        "givenName": "J.", 
        "id": "sg:person.01012241042.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012241042.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policlinico San Matteo Fondazione", 
          "id": "https://www.grid.ac/institutes/grid.419425.f", 
          "name": [
            "Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Porta", 
        "givenName": "C.", 
        "id": "sg:person.01100733105.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100733105.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic", 
          "id": "https://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rini", 
        "givenName": "B.", 
        "id": "sg:person.01113325143.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vienna General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411904.9", 
          "name": [
            "Abteilung f\u00fcr Onkologie, Allgemeines Krankenhaus, Universit\u00e4tskliniken, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schmidinger", 
        "givenName": "M.", 
        "id": "sg:person.01165240357.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165240357.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera San Camillo-Forlanini", 
          "id": "https://www.grid.ac/institutes/grid.419458.5", 
          "name": [
            "Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sternberg", 
        "givenName": "C. N.", 
        "id": "sg:person.01354346024.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354346024.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kantonsspital St. Gallen", 
          "id": "https://www.grid.ac/institutes/grid.413349.8", 
          "name": [
            "Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Putora", 
        "givenName": "P. M.", 
        "id": "sg:person.0614523204.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614523204.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2013.50.3961", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004272603"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010957301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00543-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016798994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejme1511252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017178638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3978/j.issn.2223-4683.2015.04.07", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019952281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2016.06.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022150844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2015-0145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027530924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-015-1957-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028001128", 
          "https://doi.org/10.1007/s11060-015-1957-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-015-1957-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028001128", 
          "https://doi.org/10.1007/s11060-015-1957-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00066-015-0849-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028376458", 
          "https://doi.org/10.1007/s00066-015-0849-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13014-014-0270-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040419062", 
          "https://doi.org/10.1186/s13014-014-0270-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13014-014-0270-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040419062", 
          "https://doi.org/10.1186/s13014-014-0270-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70484-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043226190"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0096316", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044299814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046531715"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00290-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048871630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2013.11.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053221475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2196/jmir.2452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069285974"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-04", 
    "datePublishedReg": "2017-04-01", 
    "description": "BACKGROUND: Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line treatment after first-line therapy with a tyrosine kinase inhibitor (TKI). Recently two phase III trials have demonstrated a potential role for nivolumab (NIV) and cabozantinib (CAB) in this setting. We aimed to estimate the impact of these trials on clinical decision making.\nMATERIALS AND METHODS: Eleven international experts were asked to provide their treatment strategies for second-line systemic therapy for mccRCC in the current setting and once NIV and CAB will be approved and available. The treatment strategies were analyzed with the objective consensus approach.\nRESULTS: The analysis of the decision trees revealed everolimus (EVE), axitinib (AXI), NIV and TKI switch (sTKI) as therapeutic options after first-line TKI therapy in the current situation and mostly NIV and CAB in the future setting. The most commonly used criteria for treatment decisions were duration of response, TKI tolerance and zugzwang a composite of several related criteria.\nCONCLUSION: In contrast to the first-line setting, recommendations for second-line systemic treatment of mccRCC among experts were not as heterogeneous. The agents mostly used after disease progression on a first-line TKI included: EVE, AXI, NIV and sTKI. In the future setting of NIV and CAB availability, NIV was the most commonly chosen drug, whereas several experts identified situations where CAB would be preferred.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00345-016-1903-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "Second-line treatment for metastatic clear cell renal cell cancer: experts\u2019 consensus algorithms", 
    "pagination": "641-648", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "41ba1dd269d1423653c29b99ae80e70a2aa9ed4ff62891a50cb5de56331909ef"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27488984"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8307716"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-016-1903-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013796886"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-016-1903-6", 
      "https://app.dimensions.ai/details/publication/pub.1013796886"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87097_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00345-016-1903-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-016-1903-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-016-1903-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-016-1903-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-016-1903-6'


 

This table displays all metadata directly associated to this object as RDF triples.

325 TRIPLES      21 PREDICATES      68 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-016-1903-6 schema:about N1f7b897316204ac0a874708712f9c100
2 N21610ef500184a6cb7801ac5a35d51c2
3 N28bd1b6658d54761ac0109f2428893f7
4 N2e0036b3258a489f86d64870354a99cd
5 N2fd605add1904b109dbf7f30812df384
6 N4ad2f070a9994c54ace9a22de194b01e
7 N56458197f74f4b31a097f13a4f5a5313
8 N6270aee483e9455384e9a96466e977cf
9 N656dd2134ccd4c31aeae2d457a65d3a3
10 N65fd1ccef7974f4c9adc03a674f89bd5
11 N66535e2f03ab4c27b2e375fc9d04e8e9
12 N740f5eebf9f245fda9cac15efcfb83ba
13 N8a45db9614094de5a3b2261569d95919
14 Nc51ffc5349b34a57b1adcc446379e2e3
15 Nc5d4950c7a214216b7c6f66aaea75f12
16 Ndb41d92aee414c578b9220ef8083b442
17 Nf54cba46a4f54227a8f4fab2dba14655
18 Nfcf8471732894ee0b4685a2673edc600
19 anzsrc-for:11
20 anzsrc-for:1102
21 schema:author N40a89cb9297747dc8ed9930d73763969
22 schema:citation sg:pub.10.1007/s00066-015-0849-8
23 sg:pub.10.1007/s11060-015-1957-0
24 sg:pub.10.1186/s13014-014-0270-y
25 https://doi.org/10.1002/cncr.25219
26 https://doi.org/10.1016/j.eururo.2013.11.023
27 https://doi.org/10.1016/j.eururo.2016.06.009
28 https://doi.org/10.1016/s0140-6736(11)61613-9
29 https://doi.org/10.1016/s1470-2045(14)70484-x
30 https://doi.org/10.1016/s1470-2045(15)00290-9
31 https://doi.org/10.1016/s1470-2045(15)00543-4
32 https://doi.org/10.1016/s1470-2045(16)30107-3
33 https://doi.org/10.1056/nejme1511252
34 https://doi.org/10.1056/nejmoa1510016
35 https://doi.org/10.1056/nejmoa1510665
36 https://doi.org/10.1093/annonc/mdu259
37 https://doi.org/10.1093/annonc/mdw160
38 https://doi.org/10.1200/jco.2013.50.3961
39 https://doi.org/10.1371/journal.pone.0096316
40 https://doi.org/10.1634/theoncologist.2015-0145
41 https://doi.org/10.2196/jmir.2452
42 https://doi.org/10.3978/j.issn.2223-4683.2015.04.07
43 schema:datePublished 2017-04
44 schema:datePublishedReg 2017-04-01
45 schema:description BACKGROUND: Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line treatment after first-line therapy with a tyrosine kinase inhibitor (TKI). Recently two phase III trials have demonstrated a potential role for nivolumab (NIV) and cabozantinib (CAB) in this setting. We aimed to estimate the impact of these trials on clinical decision making. MATERIALS AND METHODS: Eleven international experts were asked to provide their treatment strategies for second-line systemic therapy for mccRCC in the current setting and once NIV and CAB will be approved and available. The treatment strategies were analyzed with the objective consensus approach. RESULTS: The analysis of the decision trees revealed everolimus (EVE), axitinib (AXI), NIV and TKI switch (sTKI) as therapeutic options after first-line TKI therapy in the current situation and mostly NIV and CAB in the future setting. The most commonly used criteria for treatment decisions were duration of response, TKI tolerance and zugzwang a composite of several related criteria. CONCLUSION: In contrast to the first-line setting, recommendations for second-line systemic treatment of mccRCC among experts were not as heterogeneous. The agents mostly used after disease progression on a first-line TKI included: EVE, AXI, NIV and sTKI. In the future setting of NIV and CAB availability, NIV was the most commonly chosen drug, whereas several experts identified situations where CAB would be preferred.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N8b948ab5eb7d47bfa8e1cc8bf7851dfe
50 N8dd7b2554042463ab10b6632842d7848
51 sg:journal.1094127
52 schema:name Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
53 schema:pagination 641-648
54 schema:productId N83f931daa03e44b0b9e8fbc6ad737721
55 N94aaf79667d240b8a1171cc6cf7bfcfb
56 Nb5a505e979d04eb29df2409cec3b7de5
57 Nca41732950c34ef2bfd8057e876c66f0
58 Ncea79338cace47a6b0931811f184d7f3
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013796886
60 https://doi.org/10.1007/s00345-016-1903-6
61 schema:sdDatePublished 2019-04-11T12:24
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N582cc91c488e4853abbf4a61761bbd32
64 schema:url https://link.springer.com/10.1007%2Fs00345-016-1903-6
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N02e7dfce945944fd92e0d5708f97f153 rdf:first sg:person.010726400772.84
69 rdf:rest Naa5c971786b1428c929035f699c31de6
70 N1f7b897316204ac0a874708712f9c100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Indazoles
72 rdf:type schema:DefinedTerm
73 N21610ef500184a6cb7801ac5a35d51c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Pyridines
75 rdf:type schema:DefinedTerm
76 N28bd1b6658d54761ac0109f2428893f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Anilides
78 rdf:type schema:DefinedTerm
79 N2e0036b3258a489f86d64870354a99cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Antibodies, Monoclonal
81 rdf:type schema:DefinedTerm
82 N2fd605add1904b109dbf7f30812df384 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Axitinib
84 rdf:type schema:DefinedTerm
85 N3d0fb409792a43859363d2533f667b95 rdf:first sg:person.01100733105.43
86 rdf:rest N6bc9afe37398431a89b9a46dd72fc529
87 N40a89cb9297747dc8ed9930d73763969 rdf:first sg:person.01175307510.19
88 rdf:rest N646b78f44d674c1eb5495f0cf8489c09
89 N4ad2f070a9994c54ace9a22de194b01e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Everolimus
91 rdf:type schema:DefinedTerm
92 N551b0bc227f8404dbada7ecc45e20763 rdf:first sg:person.011012720634.92
93 rdf:rest Nf2791711249547beae559f100c5a625c
94 N56458197f74f4b31a097f13a4f5a5313 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Algorithms
96 rdf:type schema:DefinedTerm
97 N582cc91c488e4853abbf4a61761bbd32 schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 N6270aee483e9455384e9a96466e977cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Consensus
101 rdf:type schema:DefinedTerm
102 N646b78f44d674c1eb5495f0cf8489c09 rdf:first sg:person.01237535151.31
103 rdf:rest N551b0bc227f8404dbada7ecc45e20763
104 N656dd2134ccd4c31aeae2d457a65d3a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Protein Kinase Inhibitors
106 rdf:type schema:DefinedTerm
107 N65fd1ccef7974f4c9adc03a674f89bd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Kidney Neoplasms
109 rdf:type schema:DefinedTerm
110 N66535e2f03ab4c27b2e375fc9d04e8e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Decision Trees
112 rdf:type schema:DefinedTerm
113 N6bc9afe37398431a89b9a46dd72fc529 rdf:first sg:person.01113325143.17
114 rdf:rest N92e2e6d218bb4ac68a566b60e8453032
115 N740f5eebf9f245fda9cac15efcfb83ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Decision Support Techniques
117 rdf:type schema:DefinedTerm
118 N82eb0e4685a343acb1eb12e2feda9529 rdf:first sg:person.01354346024.40
119 rdf:rest Ne45d3216b54a46c4a3ec3276a0b32623
120 N83f931daa03e44b0b9e8fbc6ad737721 schema:name readcube_id
121 schema:value 41ba1dd269d1423653c29b99ae80e70a2aa9ed4ff62891a50cb5de56331909ef
122 rdf:type schema:PropertyValue
123 N8a45db9614094de5a3b2261569d95919 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Humans
125 rdf:type schema:DefinedTerm
126 N8b948ab5eb7d47bfa8e1cc8bf7851dfe schema:volumeNumber 35
127 rdf:type schema:PublicationVolume
128 N8dd7b2554042463ab10b6632842d7848 schema:issueNumber 4
129 rdf:type schema:PublicationIssue
130 N92e2e6d218bb4ac68a566b60e8453032 rdf:first sg:person.01165240357.56
131 rdf:rest N82eb0e4685a343acb1eb12e2feda9529
132 N94aaf79667d240b8a1171cc6cf7bfcfb schema:name doi
133 schema:value 10.1007/s00345-016-1903-6
134 rdf:type schema:PropertyValue
135 N99fecc6043784aa9a0efdab26d28b3a4 rdf:first sg:person.01315730111.15
136 rdf:rest N02e7dfce945944fd92e0d5708f97f153
137 Naa5c971786b1428c929035f699c31de6 rdf:first sg:person.0656541200.82
138 rdf:rest Nb8ec2d86847546f7b80af6ecf55421a9
139 Nb5a505e979d04eb29df2409cec3b7de5 schema:name dimensions_id
140 schema:value pub.1013796886
141 rdf:type schema:PropertyValue
142 Nb8ec2d86847546f7b80af6ecf55421a9 rdf:first sg:person.01012241042.76
143 rdf:rest N3d0fb409792a43859363d2533f667b95
144 Nc51ffc5349b34a57b1adcc446379e2e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Treatment Failure
146 rdf:type schema:DefinedTerm
147 Nc5d4950c7a214216b7c6f66aaea75f12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Antineoplastic Agents
149 rdf:type schema:DefinedTerm
150 Nca41732950c34ef2bfd8057e876c66f0 schema:name pubmed_id
151 schema:value 27488984
152 rdf:type schema:PropertyValue
153 Ncea79338cace47a6b0931811f184d7f3 schema:name nlm_unique_id
154 schema:value 8307716
155 rdf:type schema:PropertyValue
156 Ndb41d92aee414c578b9220ef8083b442 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Carcinoma, Renal Cell
158 rdf:type schema:DefinedTerm
159 Ne45d3216b54a46c4a3ec3276a0b32623 rdf:first sg:person.0614523204.76
160 rdf:rest rdf:nil
161 Nf2791711249547beae559f100c5a625c rdf:first sg:person.01304252172.82
162 rdf:rest N99fecc6043784aa9a0efdab26d28b3a4
163 Nf54cba46a4f54227a8f4fab2dba14655 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Imidazoles
165 rdf:type schema:DefinedTerm
166 Nfcf8471732894ee0b4685a2673edc600 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Nivolumab
168 rdf:type schema:DefinedTerm
169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
170 schema:name Medical and Health Sciences
171 rdf:type schema:DefinedTerm
172 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
173 schema:name Cardiorespiratory Medicine and Haematology
174 rdf:type schema:DefinedTerm
175 sg:journal.1094127 schema:issn 0724-4983
176 1433-8726
177 schema:name World Journal of Urology
178 rdf:type schema:Periodical
179 sg:person.01012241042.76 schema:affiliation https://www.grid.ac/institutes/grid.55325.34
180 schema:familyName Oldenburg
181 schema:givenName J.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012241042.76
183 rdf:type schema:Person
184 sg:person.010726400772.84 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
185 schema:familyName Larkin
186 schema:givenName J.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010726400772.84
188 rdf:type schema:Person
189 sg:person.01100733105.43 schema:affiliation https://www.grid.ac/institutes/grid.419425.f
190 schema:familyName Porta
191 schema:givenName C.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100733105.43
193 rdf:type schema:Person
194 sg:person.011012720634.92 schema:affiliation https://www.grid.ac/institutes/grid.5335.0
195 schema:familyName Eisen
196 schema:givenName T.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011012720634.92
198 rdf:type schema:Person
199 sg:person.01113325143.17 schema:affiliation https://www.grid.ac/institutes/grid.239578.2
200 schema:familyName Rini
201 schema:givenName B.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17
203 rdf:type schema:Person
204 sg:person.01165240357.56 schema:affiliation https://www.grid.ac/institutes/grid.411904.9
205 schema:familyName Schmidinger
206 schema:givenName M.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165240357.56
208 rdf:type schema:Person
209 sg:person.01175307510.19 schema:affiliation https://www.grid.ac/institutes/grid.413349.8
210 schema:familyName Rothermundt
211 schema:givenName C.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175307510.19
213 rdf:type schema:Person
214 sg:person.01237535151.31 schema:affiliation https://www.grid.ac/institutes/grid.412353.2
215 schema:familyName von Rappard
216 schema:givenName J.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237535151.31
218 rdf:type schema:Person
219 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
220 schema:familyName Escudier
221 schema:givenName B.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
223 rdf:type schema:Person
224 sg:person.01315730111.15 schema:affiliation https://www.grid.ac/institutes/grid.10423.34
225 schema:familyName Grünwald
226 schema:givenName V.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315730111.15
228 rdf:type schema:Person
229 sg:person.01354346024.40 schema:affiliation https://www.grid.ac/institutes/grid.419458.5
230 schema:familyName Sternberg
231 schema:givenName C. N.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354346024.40
233 rdf:type schema:Person
234 sg:person.0614523204.76 schema:affiliation https://www.grid.ac/institutes/grid.413349.8
235 schema:familyName Putora
236 schema:givenName P. M.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614523204.76
238 rdf:type schema:Person
239 sg:person.0656541200.82 schema:affiliation https://www.grid.ac/institutes/grid.239395.7
240 schema:familyName McDermott
241 schema:givenName D.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82
243 rdf:type schema:Person
244 sg:pub.10.1007/s00066-015-0849-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028376458
245 https://doi.org/10.1007/s00066-015-0849-8
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s11060-015-1957-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028001128
248 https://doi.org/10.1007/s11060-015-1957-0
249 rdf:type schema:CreativeWork
250 sg:pub.10.1186/s13014-014-0270-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1040419062
251 https://doi.org/10.1186/s13014-014-0270-y
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1002/cncr.25219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017587632
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/j.eururo.2013.11.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053221475
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/j.eururo.2016.06.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022150844
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/s1470-2045(14)70484-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043226190
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/s1470-2045(15)00290-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048871630
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/s1470-2045(15)00543-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016798994
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1056/nejme1511252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017178638
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1056/nejmoa1510016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010957301
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1093/annonc/mdu259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046531715
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1093/annonc/mdw160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059394727
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2013.50.3961 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004272603
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1371/journal.pone.0096316 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044299814
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1634/theoncologist.2015-0145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027530924
284 rdf:type schema:CreativeWork
285 https://doi.org/10.2196/jmir.2452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069285974
286 rdf:type schema:CreativeWork
287 https://doi.org/10.3978/j.issn.2223-4683.2015.04.07 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019952281
288 rdf:type schema:CreativeWork
289 https://www.grid.ac/institutes/grid.10423.34 schema:alternateName Hannover Medical School
290 schema:name Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany
291 rdf:type schema:Organization
292 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
293 schema:name Gustave Roussy, Villejuif, France
294 rdf:type schema:Organization
295 https://www.grid.ac/institutes/grid.239395.7 schema:alternateName Beth Israel Deaconess Medical Center
296 schema:name Beth Israel Deaconess Medical Center, Boston, MA, USA
297 rdf:type schema:Organization
298 https://www.grid.ac/institutes/grid.239578.2 schema:alternateName Cleveland Clinic
299 schema:name Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.411904.9 schema:alternateName Vienna General Hospital
302 schema:name Abteilung für Onkologie, Allgemeines Krankenhaus, Universitätskliniken, Vienna, Austria
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.412353.2 schema:alternateName University Children’s Hospital Bern
305 schema:name Department of Nephrology, University Hospital Bern, Bern, Switzerland
306 rdf:type schema:Organization
307 https://www.grid.ac/institutes/grid.413349.8 schema:alternateName Kantonsspital St. Gallen
308 schema:name Department of Haematology and Oncology, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland
309 Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.419425.f schema:alternateName Policlinico San Matteo Fondazione
312 schema:name Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy
313 rdf:type schema:Organization
314 https://www.grid.ac/institutes/grid.419458.5 schema:alternateName Azienda Ospedaliera San Camillo-Forlanini
315 schema:name Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
316 rdf:type schema:Organization
317 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
318 schema:name The Royal Marsden Hospital, London, UK
319 rdf:type schema:Organization
320 https://www.grid.ac/institutes/grid.5335.0 schema:alternateName University of Cambridge
321 schema:name Department of Oncology, Cambridge University Hospitals NHS Foundation Cambridge, Cambridge, UK
322 rdf:type schema:Organization
323 https://www.grid.ac/institutes/grid.55325.34 schema:alternateName Oslo University Hospital
324 schema:name Department of Medical Oncology, Norwegian Radium Hospital, Oslo, Norway
325 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...